NEX-I Company Description
NEX-I, Inc. develops, manufactures, and markets drugs and immunotherapies for cancer.
The company develops Phase 1 products, including NXI-101 and NXI-201, which are monoclonal antibodies, as well as various candidate products, such as NXI-S160, NXI-S301, and NXI-S172, which are antibody-drug conjugates, and NXI-401, a monoclonal antibody drug.
It also develops and provides NEXORA, a therapeutics platform; ONCOKINE, a factor associated with resistance to immuno-oncology therapies that suppresses tumor growth and induces immune cell activation in the tumor microenvironment; and SMRT, an immunotherapy in which resistant cancer cells alter the tumor microenvironment into an immunosuppressive state or acquire immune evasion mechanisms through the expression of specific cell surface proteins.
The company was founded in 2021 and is headquartered in Seoul, South Korea.
| Country | South Korea |
| Founded | 2021 |
| CEO | Kyoung Wan Yoon |
Contact Details
Address: 201 Songpa-daero Seoul South Korea | |
| Phone | 82 2 6951 0412 |
| Website | nex-i.co.kr |
Stock Details
| Ticker Symbol | 493410 |
| Exchange | KOSDAQ |
| Stock Type | Common Stock |
| Reporting Currency | KRW |
| ISIN Number | KR7493410005 |
Key Executives
| Name | Position |
|---|---|
| Kyoung Wan Yoon | Chief Executive Officer |
| Jaemyoung Shim | Chief Financial Officer |